Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells

Proteasome Inhibitor ◽

Carcinoma Cells ◽

Synergistic Interaction ◽

The Novel ◽

Platinum Sensitive ◽

Ovarian Carcinoma Cells ◽

Abstract C34: Synergistic interaction between a novel histone deacetylase inhibitor and the proteasome inhibitor bortezomib in platinum-resistant ovarian carcinoma cells.

10.1158/1535-7163.targ-11-c34 ◽

2011 ◽

Author(s):

Laura Gatti ◽

Valentina Benedetti ◽

Michelandrea De Cesare ◽

Elisabetta Corna ◽

Raffaella Cincinelli ◽

...

Keyword(s):

Ovarian Carcinoma ◽

Histone Deacetylase ◽

Proteasome Inhibitor ◽

Carcinoma Cells ◽

Synergistic Interaction ◽

Ovarian Carcinoma Cells ◽

Platinum Resistant ◽

Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: Enhanced DNA damage response

International Journal of Cancer ◽

10.1002/ijc.24819 ◽

2009 ◽

pp. NA-NA

Author(s):

Valentina Zuco ◽

Valentina Benedetti ◽

Michelandrea De Cesare ◽

Franco Zunino

Keyword(s):

Dna Damage ◽

Ovarian Carcinoma ◽

Histone Deacetylase ◽

Dna Damage Response ◽

Carcinoma Cells ◽

Ovarian Carcinoma Cells ◽

Deacetylase Inhibitor ◽

Damage Response

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

European Journal Of Haematology ◽

10.1111/j.1600-0609.2009.01239.x ◽

2009 ◽

Vol 82 (6) ◽

pp. 440-449 ◽

Cited By ~ 67

Author(s):

Ulrike Heider ◽

Jessica Rademacher ◽

Britta Lamottke ◽

Maren Mieth ◽

Markus Moebs ◽

...

Keyword(s):

T Cell ◽

Histone Deacetylase ◽

Proteasome Inhibitor ◽

Cell Lymphoma ◽

Synergistic Interaction ◽

T Cell Lymphoma ◽

Cutaneous T Cell Lymphoma ◽

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

Investigational New Drugs ◽

10.1007/s10637-011-9766-6 ◽

2011 ◽

Vol 30 (6) ◽

pp. 2303-2317 ◽

Cited By ~ 87

Author(s):

Michael Millward ◽

Timothy Price ◽

Amanda Townsend ◽

Christopher Sweeney ◽

Andrew Spencer ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Trial ◽

Histone Deacetylase ◽

Proteasome Inhibitor ◽

Phase 1 ◽

The Novel ◽

Phase 1 Clinical Trial ◽

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma

European Journal Of Haematology ◽

10.1111/j.1600-0609.2007.00995.x ◽

2007 ◽

Vol 80 (2) ◽

pp. 133-142 ◽

Cited By ~ 79

Author(s):

Ulrike Heider ◽

Ivana von Metzler ◽

Martin Kaiser ◽

Marleen Rosche ◽

Jan Sterz ◽

...

Keyword(s):

Mantle Cell Lymphoma ◽

Histone Deacetylase ◽

Proteasome Inhibitor ◽

Cell Lymphoma ◽

Synergistic Interaction ◽

Deacetylase Inhibitor ◽

Mantle Cell

The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells

BMC Cancer ◽

10.1186/s12885-014-1003-1 ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 7

Author(s):

Ki Cheong Park ◽

Jun Hyeok Heo ◽

Jeong Yong Jeon ◽

Hye Ji Choi ◽

A Ra Jo ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Antitumor Activity ◽

Cell Carcinoma ◽

Histone Deacetylase ◽

Renal Cell ◽

Carcinoma Cells ◽

The Novel ◽

Cytochrome C Release ◽

Induction of Apoptosis and Chemosensitization by the Histone Deacetylase Inhibitor Trichostatin in Hepatocellular Carcinoma Cells: Molecular Analysis and RKIP Levels

Forum on Immunopathological Diseases and Therapeutics ◽

10.1615/forumimmundisther.v2.i2.40 ◽

2011 ◽

Vol 2 (2) ◽

pp. 127-135 ◽

Cited By ~ 2

Author(s):

Luigi Inguglia ◽

Monica Notarbartolo ◽

Paola Poma ◽

Manuela Labbozzetta ◽

Natale D'Alessandro

Keyword(s):

Hepatocellular Carcinoma ◽

Histone Deacetylase ◽

Molecular Analysis ◽

Carcinoma Cells ◽

Hepatocellular Carcinoma Cells ◽

Deacetylase Inhibitor ◽

Histone Deacetylase Inhibitor Trichostatin ◽

Induction Of Apoptosis

The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest

Cell Biochemistry and Function ◽

10.1002/cbf.3359 ◽

2018 ◽

Vol 36 (8) ◽

pp. 398-407 ◽

Cited By ~ 1

Author(s):

Yin-Wei Cheng ◽

Lian-Di Liao ◽

Qian Yang ◽

Yang Chen ◽

Ping-Juan Nie ◽

...

Keyword(s):

Cell Cycle ◽

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Histone Deacetylase ◽

Carcinoma Cells ◽

Cycle Arrest ◽

Anticancer Effects ◽

Apoptotic effects of the novel histone deacetylase inhibitor BML-210 on HeLa cells

Biologija ◽

10.2478/v10054-008-0044-2 ◽

2008 ◽

Vol 54 (3) ◽

pp. 217-220

Author(s):

V. V. Borutinskaite ◽

J. Savickiene ◽

R. Navakauskiene

Keyword(s):

Histone Deacetylase ◽

Hela Cells ◽

The Novel ◽

Deacetylase Inhibitor ◽

Apoptotic Effects

Abstract 799: The novel histone deacetylase inhibitor pracinostat is an effective anti-lymphoma agent

10.1158/1538-7445.am2018-799 ◽

2018 ◽

Author(s):

Afua A. Mensah ◽

Filippo Spriano ◽

Eugenio Gaudio ◽

Chiara Tarantelli ◽

Luciano Cascione ◽

...

Keyword(s):

Histone Deacetylase ◽

The Novel ◽